DNA vaccines for targeting bacterial infections

被引:75
作者
Ingolotti, Mariana [1 ,2 ]
Kawalekar, Omkar [1 ]
Shedlock, Devon J. [1 ]
Muthumani, Karuppiah [1 ]
Weiner, David B. [1 ]
机构
[1] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
[2] Austral Univ, Dept Anat, Sch Biomed Sci, Buenos Aires, DF, Argentina
关键词
bacterial vaccine; cellular and humoral immune responses; DNA vaccine; molecular adjuvants; ATTENUATED SALMONELLA-TYPHIMURIUM; ANTIGEN-PRESENTING CELLS; HEAT-SHOCK-PROTEIN; MHC CLASS-I; IMMUNE-RESPONSES; PLASMID DNA; PROTECTIVE IMMUNITY; INTRAMUSCULAR IMMUNIZATION; MYCOBACTERIUM-TUBERCULOSIS; LISTERIA-MONOCYTOGENES;
D O I
10.1586/ERV.10.57
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
DNA vaccination has been of great interest since its discovery in the 1990s due to its ability to elicit both humoral and cellular immune responses. DNA vaccines consist of a DNA plasmid containing a transgene that encodes the sequence of a target protein from a pathogen under the control of a eukaryotic promoter. This revolutionary technology has proven to be effective in animal models and four DNA vaccine products have recently been approved for veterinary use. Although few DNA vaccines against bacterial infections have been tested, the results are encouraging. Because of their versatility, safety and simplicity a wider range of organisms can be targeted by these vaccines, which shows their potential advantages to public health. This article describes the mechanism of action of DNA vaccines and their potential use for targeting bacterial infections. In addition, it provides an updated summary of the methods used to enhance immunogenicity from codon optimization and adjuvants to delivery techniques including electroporation and use of nanoparticles.
引用
收藏
页码:747 / 763
页数:17
相关论文
共 198 条
[1]   Overview of Vaccines and vaccination [J].
Ada, G .
MOLECULAR BIOTECHNOLOGY, 2005, 29 (03) :255-271
[2]  
Agarwal K, 2008, MAYO CLIN PROC, V83, P169, DOI 10.4065/83.2.169
[3]  
Angel Jonathan B, 2008, J Immune Based Ther Vaccines, V6, P4, DOI 10.1186/1476-8518-6-4
[4]  
Apostolopoulos V, 2009, EXPERT REV VACCINES, V8, P1133, DOI [10.1586/erv.09.94, 10.1586/ERV.09.94]
[5]   Protective immunity against porcine circovirus 2 in mice induced by a gene-based combination vaccination [J].
Aravindaram, Kandan ;
Kuo, Tsun-Yung ;
Lan, Chun-Wen ;
Yu, Hsiu-Hui ;
Wang, Pei-Hsueh ;
Chen, Yu-San ;
Chen, Gabriel Hsu-Chung ;
Yang, Ning-Sun .
JOURNAL OF GENE MEDICINE, 2009, 11 (04) :288-301
[6]   Haemophilus influenzae type b antibodies in vaccinated and non-vaccinated children [J].
Arvas, Ahmet ;
Gur, Emel ;
Bahar, Hrisi ;
Torun, Muzeyyen M. ;
Demirci, Mehmet ;
Aslan, Mustafa ;
Kocazeybek, Bekir .
PEDIATRICS INTERNATIONAL, 2008, 50 (04) :469-473
[7]   Cytokines as adjuvants for avian vaccines [J].
Asif, M ;
Jenkins, KA ;
Hilton, LS ;
Kimpton, WG ;
Bean, AGD ;
Lowenthal, JW .
IMMUNOLOGY AND CELL BIOLOGY, 2004, 82 (06) :638-643
[8]  
ATANASIU P, 1962, CR HEBD ACAD SCI, V254, P2250
[9]   Yersinia enterocolitica:: Subversion of adaptive immunity and implications for vaccine development [J].
Autenrieth, Stella E. ;
Autenrieth, Ingo B. .
INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, 2008, 298 (1-2) :69-77
[10]   Towards a human oral vaccine for anthrax: The utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategy [J].
Baillie, Leslie W. J. ;
Rodriguez, Ana L. ;
Moore, Stephen ;
Atkins, Helen S. ;
Feng, Chiguang ;
Nataro, James R. ;
Pasetti, Marcela F. .
VACCINE, 2008, 26 (48) :6083-6091